UROGEN PHARMA LTD
URGNNASDAQ🏆 #1756 by market capEarnings Nov 5US Equity
$48.24▲ $1.15 (+2.39%)
Live1h—
24h▲ 2.4%
7d—
14d—
30d—
1y—
🏦Market Cap
$2.35B
Small Cap
📈Revenue Growth (YoY)
+21.4%
Healthy
📊Gross Margin
90.8%
High
💵FCF Margin
-84.3%
Thin
⚖️P/S Ratio
12.5x
Elevated
Otter Score
66
Fair
📊
Analyst Ratings
Price
$48.24
Total
16
Raised
0
Lowered
2
Avg PT
$53.40
H / L
$75 / $40
| Institution | Action | Rating | Date |
|---|---|---|---|
HC Wainwright & Co. | Reiterated | Buy | 2026-08-06 |
Guggenheim | Reiterated | Buy | 2026-08-06 |
TD Cowen | Reiterated | Buy | 2026-08-05 |
Oppenheimer | Reiterated | Outperform | 2026-07-16 |
D. Boral Capital | Reiterated | Buy | 2026-03-31 |
Scotiabank | Reiterated | Sector Outperform | 2025-06-13 |
Goldman Sachs | Reiterated | Neutral | 2025-05-22 |
EF Hutton | Reiterated | Buy | 2024-11-06 |
Ladenburg Thalmann | Reiterated | Buy | 2024-06-14 |
Jefferies | Downgraded | Buy → Hold | 2023-02-08 |
Berenberg | Reiterated | Buy | 2022-09-06 |
H.C. Wainwright | Reiterated | Buy | 2020-04-16 |
JP Morgan | Reiterated | Neutral | 2019-11-13 |
Stifel Nicolaus | Reiterated | Buy | 2018-09-14 |
Raymond James | Downgraded | Outperform → Market Perform | 2017-11-15 |
Cowen & Co. | Reiterated | Outperform | 2017-05-30 |
One row per institution, most recent rating